The Journal of dermatological treatment最新文献_第4页

Patient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-11 DOI: 10.1080/09546634.2025.2476576

Raj Chovatiya, Christy H Chang, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H Chu, Diane Hanna, Melissa S Seal, Matthew Zirwas

{"title":"Patient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States.","authors":"Raj Chovatiya, Christy H Chang, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H Chu, Diane Hanna, Melissa S Seal, Matthew Zirwas","doi":"10.1080/09546634.2025.2476576","DOIUrl":"https://doi.org/10.1080/09546634.2025.2476576","url":null,"abstract":"Introduction: Seborrheic dermatitis (SD) affects a large, diverse population and is associated with significant morbidity/burden.Methods: The Harris Poll conducted online surveys to understand the perceptions, preferences, and experiences regarding treatments of US patients with SD and dermatology healthcare providers (HCPs) from December 2021 to January 2022.Results: In this survey, patients using SD treatment invested on average 34 min/d treating SD with 5.9 different treatments/week (cost: ∼$650/year). HCPs underestimated duration of SD treatment (16 min/d). Most patients agreed current treatment options are too time-consuming (61%), and would be more likely to continue a regimen with fewer treatments (88%). Few patients were 'very satisfied' with treatment option affordability (19%) and prescription treatment effectiveness (25%); only 8.7% of HCPs were satisfied with prescription SD treatment options available. Most patients acknowledged SD was difficult to treat (73%) and were interested in trying new treatments (87%). HCPs expressed the need for new treatments (92%) and agreed patients would be interested in trying them (95%). Patients prioritized symptom relief over look/feel of product and regimens that could be easily incorporated into hair routines. Patients would like HCPs to consider skin tone when recommending treatments (81%) and agreed cultural background affects treatment preference (55%).Conclusions: These findings suggest a need for SD treatments that address patient concerns/frustrations with current time-intensive complex regimens, and consider diverse hair care routines/cultural backgrounds.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2476576"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lessons from a decentralized trial in atopic dermatitis: promises and perils.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-03 DOI: 10.1080/09546634.2025.2480747

Zhihong Lai, Candice M Estes, Stephanie Lyke, Haq Nawaz

引用次数: 0

Anatomical considerations for thread-based brow lifting and wrinkle treatment.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-30 DOI: 10.1080/09546634.2024.2448265

Gi-Woong Hong, Jovian Wan, Song-Eun Yoon, Sky Wong, Kyu-Ho Yi

{"title":"Anatomical considerations for thread-based brow lifting and wrinkle treatment.","authors":"Gi-Woong Hong, Jovian Wan, Song-Eun Yoon, Sky Wong, Kyu-Ho Yi","doi":"10.1080/09546634.2024.2448265","DOIUrl":"https://doi.org/10.1080/09546634.2024.2448265","url":null,"abstract":"This review explores the anatomical considerations and technical aspects of thread lifting for the forehead and eyebrow, focusing on the relationships between vascular structures, muscular anatomy, and age-related changes in the forehead-eyebrow complex. It highlights the critical importance of understanding neurovascular pathways, particularly the supratrochlear and supraorbital vessels, as well as the appropriate thread placement techniques necessary for optimal outcomes. The review demonstrates that I-shaped threads, when placed beneath the frontalis muscle, provide a safer and equally effective alternative to traditional U-shaped designs. Additionally, the review emphasizes the significance of preoperative assessment, especially the evaluation of tissue mobility and adhesion patterns, in predicting procedural success. The review concludes that combining thread lifting with volumising monofilaments offers a comprehensive approach to rejuvenating the forehead-glabellar region, while minimizing the risk of complications. This study's clinical impact lies in its potential to enhance both the safety and efficacy of thread lifting procedures, offering practitioners a refined technique for esthetic rejuvenation of the forehead and eyebrow complex.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2448265"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-02 DOI: 10.1080/09546634.2024.2438794

Francine Foss, Youn H Kim, Julia Scarisbrick, Oleg Akilov, Robert Ristuccia, Karen Dwyer, Wende Wu, Martine Bagot

{"title":"Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.","authors":"Francine Foss, Youn H Kim, Julia Scarisbrick, Oleg Akilov, Robert Ristuccia, Karen Dwyer, Wende Wu, Martine Bagot","doi":"10.1080/09546634.2024.2438794","DOIUrl":"https://doi.org/10.1080/09546634.2024.2438794","url":null,"abstract":"Purpose: Mogamulizumab demonstrated improved outcomes vs. vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.Materials and methods: This post-hoc analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.Results: A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab vs. vorinostat arm. Long-term response was also observed in mogamulizumab-treated patients with more advanced disease (stage IVA1 [17/20], B2 blood involvement [18/20], and SS [14/20]). PFS was significantly longer (9.4 vs. 3.1 months; p < 0.0001) in mogamulizumab vs. vorinostat-treated patients taking concomitant steroids. Mogamulizumab-treated patients experienced longer TTNT vs. vorinostat. Lymphopenia and MAR were associated with response to mogamulizumab.Conclusions: MAVORIC demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without MAR.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2438794"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effective and safe surgery for keratinocyte skin cancer in the elderly over 80 years of age: a single-institution retrospective study of 345 patients over one year.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-04 DOI: 10.1080/09546634.2025.2461650

Luca D Fontana, Clara Richter, Ramon Lang, Christian Greis, Jürg Hafner

{"title":"Effective and safe surgery for keratinocyte skin cancer in the elderly over 80 years of age: a single-institution retrospective study of 345 patients over one year.","authors":"Luca D Fontana, Clara Richter, Ramon Lang, Christian Greis, Jürg Hafner","doi":"10.1080/09546634.2025.2461650","DOIUrl":"https://doi.org/10.1080/09546634.2025.2461650","url":null,"abstract":"Objectives: As life expectancy rises and the population continues to age, physicians will be faced with an increasing number of elderly patients with keratinocyte cancer (KC). This study aims to better characterize KC surgery in patients over 80 years of age, with a particular focus on the incidence of postoperative complications.Methods: A retrospective study was conducted on all patients aged 80 years and older who underwent surgery for KC at the University Hospital of Zurich in 2022. Data were collected from operative and postoperative notes within six months after surgery.Results: A total of 565 tumors were removed from 345 patients, consisting mainly of basal cell carcinoma (46.5%) and squamous cell carcinoma (45.8%), including 24.2% clinically large tumors (>2 cm in diameter). A total of 26 complications were recorded, resulting in an overall complication rate of4.6%. Only one patient with a hematoma required surgical revision under local anaesthesia. Four cases of hemorrhage were solved by bed side ligations under local anaesthesia. Of the 26 recorded complications, 15 (58%) concerned wound dehiscence, requiring no further measures. The use of novel oral anticoagulants, lower extremity location, surgical specimen size >2 cm2, and flap repair were found to be independent risk factors associated with a statistically higher incidence of complications.Conclusions: This study demonstrated that dermatologic surgery adapted to the geriatric population is relatively safe and effective, even for larger KC of several centimeters in diameter.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2461650"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review. Janus激酶抑制剂和生物制剂治疗类活体血管病变：系统综述。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-19 DOI: 10.1080/09546634.2025.2451804

Yu Liu, Tingting Li, Wei Shi

{"title":"Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review.","authors":"Yu Liu, Tingting Li, Wei Shi","doi":"10.1080/09546634.2025.2451804","DOIUrl":"https://doi.org/10.1080/09546634.2025.2451804","url":null,"abstract":"Purpose: Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with an unclear pathogenesis, potentially involving hypercoagulability and inflammation. This systematic review aims to evaluate the efficacy and safety of Janus kinase (JAK) inhibitors and biologics in the treatment of LV.Materials and methods: A comprehensive search was conducted in PubMed, EMBASE, and the Cochrane Library on June 10, 2024, to identify relevant studies evaluating the use of JAK inhibitors and biologics in LV treatment.Results: A total of 15 articles were included in the review. Among the 41 patients treated with biologics and JAK inhibitors, 36 (87.8%) showed positive clinical responses, including significant improvements in pain relief. TNF-α inhibitors were the most commonly used monotherapy, followed by JAK inhibitors. Adverse events were infrequent, suggesting that these treatments generally have a favorable safety profile.Conclusions: JAK inhibitors and biologics appear to be safe and effective alternatives for managing refractory LV. These findings provide a foundation for future studies to further validate their clinical effectiveness and long-term safety.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2451804"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-03 DOI: 10.1080/09546634.2025.2460578

Filip Rob, Blanka Pinkova, Kristyna Sokolova, Jana Kopuleta, Zuzana Jiraskova Zakostelska, Jana Cadova

{"title":"Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study.","authors":"Filip Rob, Blanka Pinkova, Kristyna Sokolova, Jana Kopuleta, Zuzana Jiraskova Zakostelska, Jana Cadova","doi":"10.1080/09546634.2025.2460578","DOIUrl":"https://doi.org/10.1080/09546634.2025.2460578","url":null,"abstract":"In this multicentric real-world observational retrospective study, we evaluated the efficacy and safety of dupilumab for atopic dermatitis in children <6 years of age who underwent a minimum of 16 weeks of therapy. The analysis focused on EASI (Eczema Area and Severity Index), CDLQI (Children's Dermatology Life Quality Index), and Itch NRS (Numeric Rating Scale) changes from baseline to 4, 16, 24, 48, 72, and 96 weeks of follow-up (when available). Overall 24 children were included, with a mean age of 4.4 years. The baseline mean EASI among these patients was 26.7 (range 11.2-42.5). Since week 16 of therapy, all patients achieved and sustained at least 50% (EASI-50) atopic dermatitis improvement from baseline for the remainder of the follow-up period. At week 16, the mean EASI was 4.6 (0.8-13.1), EASI-75 reached 75% and EASI-90 38% of the patients. Within the initial 16 weeks of dupilumab treatment, 50% of patients experienced at least one adverse event, none of which were deemed severe. Conjunctivitis was among the most common adverse events (8.3%). In conclusion, dupilumab exhibited favorable tolerability, efficacy, and safety in children diagnosed with atopic dermatitis who were below the age of 6.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2460578"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-10 DOI: 10.1080/09546634.2024.2432932

E Mortato, F Artosi, C Borselli, I Compagnucci, Antonia Rivieccio, C Lanna, S Lambiase, R Gaeta Shumak, F Loconsole, L Bianchi, E Campione

{"title":"Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics.","authors":"E Mortato, F Artosi, C Borselli, I Compagnucci, Antonia Rivieccio, C Lanna, S Lambiase, R Gaeta Shumak, F Loconsole, L Bianchi, E Campione","doi":"10.1080/09546634.2024.2432932","DOIUrl":"https://doi.org/10.1080/09546634.2024.2432932","url":null,"abstract":"Purpose: Psoriasis is a chronic, immune-mediated inflammatory skin condition marked by erythematous, scaly plaques. This retrospective observational study evaluated the long-term efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor, in treating moderate to severe plaque psoriasis in 56 patients across two dermatology clinics in Italy.Materials and methods: Adult participants with a baseline Psoriasis Area and Severity Index (PASI) >10, or <10 with sensitive area involvement, were followed for 16 to 52 weeks. Clinical outcomes were measured by PASI 75, 90, and 100 responses and Dermatology Life Quality Index (DLQI) scores at 4, 16, 36, and 52 weeks.Results: At week 16, 97.5% of patients achieved PASI 75, 76.7% reached PASI 90, and 66% attained PASI 100. By week 52, 91.5% achieved PASI 90 and 85.1% reached PASI 100, with 95.7% reporting a Dermatology Life Quality Index (DLQI) score of 0 or 1, indicating minimal impact on daily life. The study found similar efficacy across bio-naïve and bio-experienced groups, and between normal-weight and obese patients, without statistically significant differences. The safety profile was consistent with previous trials, with oral candidiasis as the most frequent adverse event (21%).Conclusions: These findings support the efficacy and tolerability of bimekizumab for long-term psoriasis management.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2432932"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative observation of the efficacy of Q-switched Nd:YAG laser with PhotoAcoustic Technology Pulse vs. traditional mode in treating melasma.

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-12 DOI: 10.1080/09546634.2025.2477257

Chen Ke, Yuzhen Huang, Changhan Chen, Xiaxia Chen, Youhui Ke

{"title":"Comparative observation of the efficacy of Q-switched Nd:YAG laser with PhotoAcoustic Technology Pulse vs. traditional mode in treating melasma.","authors":"Chen Ke, Yuzhen Huang, Changhan Chen, Xiaxia Chen, Youhui Ke","doi":"10.1080/09546634.2025.2477257","DOIUrl":"https://doi.org/10.1080/09546634.2025.2477257","url":null,"abstract":"Background: Melasma is a common pigmentary skin disorder. Q-switched Nd:YAG laser therapy is commonly used, but its efficacy is limited. PhotoAcoustic Technology Pulse (PTP) mode is a newer technology that may enhance treatment outcomes.Objectives: To explore the comparative efficacy and safety of the Q-switched Nd:YAG laser with PTP mode versus the traditional single-pulse mode in the treatment of melasma.Methods: A retrospective study was conducted on 129 patients with chloasma in Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine from November 2016 to December 2018. The control group received the treatment with traditional mode. The study group was treated using PTP mode. The efficacy was evaluated using the Melasma Area and Severity Index (MASI) scores and patient satisfaction assessments.Results: The effective rate was 47.69% in the control group and 59.38% in the study group. There was a statistically significant improvement in MASI scores in both groups compared to baseline (p < 0.05), with the difference between the two groups also being statistically significant (p < 0.05).Conclusion: The Q-switched Nd:YAG laser treatment in PTP mode demonstrated superior efficacy in treating melasma compared to the traditional single-pulse mode, as evidenced by statistically significant improvements in MASI scores and higher patient satisfaction rates.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2477257"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline. 用spesolimab，中剂量皮质类固醇和米诺环素成功治疗依那西普和阿达木单抗耐药坏疽性脓皮病。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-19 DOI: 10.1080/09546634.2025.2451811

Hanlin Zhang, Chao Wu, Hongzhong Jin

{"title":"Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline.","authors":"Hanlin Zhang, Chao Wu, Hongzhong Jin","doi":"10.1080/09546634.2025.2451811","DOIUrl":"https://doi.org/10.1080/09546634.2025.2451811","url":null,"abstract":"Purpose: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis characterized by rapidly developing, painful ulcers. This study explores the potential of spesolimab, an anti-IL-36R antibody, as a therapeutic option for refractory PG.Materials and methods: We report a case of a 48-year-old male with refractory PG who failed to respond to etanercept and adalimumab. Upon admission, the patient presented with extensive, painful ulcerations on the trunk and extremities. He was started on oral methylprednisolone (32 mg/day) and minocycline (50 mg twice daily). After a week, minimal improvement was observed. After reviewing the screening results and discussing treatment options, the patient received two doses of spesolimab (900 mg intravenously) administered two weeks apart.Results: Marked clinical improvement was observed after spesolimab initiation. Complete ulcer healing was achieved within six weeks of starting spesolimab, with no adverse effects reported.Conclusions: This case demonstrates the potential efficacy of spesolimab for treating refractory PG, particularly in patients unresponsive to TNF-α inhibitors. Despite the added complexity of the patient's underlying HBV infection and elevated M-protein, no HBV reactivation or other hematologic complications occurred. Further studies are needed to validate its role in managing PG and other neutrophilic dermatoses.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2451811"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0